Implications of protein flexibility for drug discovery

Nature Reviews Drug Discovery

Volumn 2, Issue 7, 2003, Pages 527-541

  Teague, Simon J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLMOCIMYCIN; 4 [5 (4 BROMOPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ACETYLCHOLINE; ADENOSINE DERIVATIVE; BARBITURIC ACID DERIVATIVE; CAPRAVIRINE; CARBONATE DEHYDRATASE INHIBITOR; CELECOXIB; DECAMETHONIUM; DONEPEZIL; FLUCONAZOLE; FLUFENAMIC ACID; HYDROXAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE; INDOMETACIN; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NEW DRUG; OSELTAMIVIR; PROTEIN; RALOXIFENE; SIALIDASE INHIBITOR; TAMOXIFEN; THYMIDYLATE SYNTHASE INHIBITOR; TOLRESTAT; TRIFLUOPERAZINE; UNINDEXED DRUG; ZOPOLRESTAT; LIGAND;

BINDING AFFINITY; BINDING KINETICS; BINDING SITE; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; ENERGY; LIPOPHILICITY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; TOXICOLOGY; THERMODYNAMICS;

DRUG DESIGN; LIGANDS; PROTEIN CONFORMATION; THERMODYNAMICS;

EID: 0037666888     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1129     Document Type: Review

References (91)

1. Bursavich, M. G. & Rich, D. H. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 45, 541-558 (2002).
2. Marvin, J. S. & Hellinga, H. W. Manipulation of ligand binding affinity by exploitation of conformational coupling. Nature Struct. Biol. 8, 795-798 (2001).
3. Baldwin, R. L. Making a network of hydophobic clusters. Science 295, 1657-1658 (2002).
4. Oefner, C. et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartyl proteases. Chem. Biol. 6, 127-131 (1999).
5. Weichsel, A. & Montford, W. R. Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89. Nature Struct. Biol. 2, 1095-1101 (1995).
6. Falke, J. J. A moving story. Science 295, 1480-1481 (2002).
7. Eisenmesser, E. Z., Bosco, D. A., Akke, M. & Kern, D. Enzyme dynamics during catalysis. Science 295, 1520-1523 (2002).
8. Lee, A. Y., Gulnik, S. V. & Erickson, J. W. Conformational switching in an aspartic protainase. Nature Struct. Biol. 5, 866-871 (1998).
9. Rahuel, J., Priestle, J. P. & Grutter, M. G. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analogue inhibitor. J. Struct. Biol. 107, 227-236 (1991).
10. Kenakin, T. Agonist receptor efficacy 1: mechanisms of efficacy and receptor promiscuity. Trends Pharmacol. Sci. 16, 188-192 (1995).
11. Ma, B., Shatsky, M., Wolfson, H. J. & Nussinov, R. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Protein Sci. 11, 184-197 (2002).
12. Shoichet, B. K., Baase, W. A., Kuroki, R. & Matthews, B. A relationship between protein stability and protein function. Proc. Natl Acad. Sci. USA 92, 452-456 (1995).
13. Gerstein, M., Lesk, A. M. & Chothia, C. Structural mechanisms for domain movements in proteins. Biochemistry 33, 6739-6749 (1994).
14. Davis, A. M. & Teague, S. J. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis, Angew. Chem. Int. Ed. Engl. 38, 736-749 (1999).
15. Kryger, G., Silman, I. & Sussman, J. L. Structure of acetycholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 7, 297-307 (1999).
16. Smith, G. M. et al. Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci. 3, 118-125 (1994).
17. Baldwin, J. J. et al. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J. Med. Chem. 32, 2510-2513 (1989).
18. Harel, M. et al. Three-dimensional structures of Drosophilia melanogaster acetylcholinesterase and of its complexes with two potent inhibitors. Protein Sci. 9, 1063-1072 (2000).
19. Zidek, L., Novotny, M. V. & Stone, M. J. Increased protein backbone conformational entropy upon hydrophobic ligand binding. Nature Struct. Biol. 6, 1118-1121 (1999).
20. Yaremchuk, A., Tukalo, M., Grotli, M. & Cusack, S. A succession of substrate induced conformational changes ensures the amino acid specificity of Thermus thermophilus prolyl-tRNA synthetase: comparison with histidyl-tRNA synthetase. J. Mol. Biol. 309, 989-1002 (2001).
21. Velazquez-Campoy, A., Luque, I. & Freire, E. The application of thermodynamic methods in drug design. Thermochimica Acta 380, 217-227 (2001).
22. Najmanovich, R., Kuttner, J., Sobolev, V. & Edelman, M. Side-chain flexibility in proteins upon ligand binding. Proteins 39, 261-268 (2000).
23. Ren, J. et al. High resolution structures of HIV-1RT from four RT-inhibitor complexes. Nature Struct. Biol. 2, 293-302 (1995).
24. Klabunde, T. et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nature Struct. Biol. 312-321 (2000).
25. Smerdon, S. J. et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 91, 3911-3915 (1994).
26. Esnouf, R. et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 2, 303-308 (1995).
27. Oikonomakos, N. G., Skamnaki, V. T., Tsitsanou, K. E., Gavalas, N. G. & Johnson, L. N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure 8, 575-584 (2000).
28. Zographos, S. E. et al. The structure of glycogen phosphorylase b with an alkyl-dihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure 5, 1413-1425 (1997).
29. Wright, S. W. et al. Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. J. Med. Chem. 45, 3865-3877 (2002).
30. Abraham, D. J. et al. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 31, 9141-9149 (1992).
31. Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Struct. Biol. 9, 268-272 (2002).
32. Ashani, Y., Peggins, J. O. III. & Doctor, B. P. Mechanism of inhibition of cholinesterases by huperzine A. Biochem. Biophys. Res. Common. 184, 719-726 (1992).
33. Graul, A., Leeson, P. A. & Castaner, J. Oseltamivir phosphate: anti-influenza, neuraminidase (sialidase) inhibitor Drugs Future 24, 1189-1202 (1999).
34. Wang, M. Z., Tai, C. Y. & Mendel, D. B. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46, 3809-3816 (2002).
35. Kulmacz, R. & Lands, W. E. M. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J. Biol. Chem. 260, 12572-12578 (1985).
36. Gierse, J. K., Koboldt, C. M., Walker, M. C. Seibert, K. & Isakson, P. C. Kinetic basis for selective inhibition of cyclooxygenases. Biochem. J. 339, 607-614 (1999).
37. Fritz, T. A., Tondi, D., Finer-Moore, J. S., Costi, M. P. & Stroud, R. M. Predicting and harnessing protein flexibility in the design of species-specific inhibitors of thymidylate synthase 1,2. Chem. Biol. 8, 981-995 (2001).
38. Stroud, R. M. & Finer-Moore, J. S. Conformational dynamics along an enzymatic reaction pathway: thymidylate synthase, 'the movie'. Biochemistry 42, 239-247 (2003).
39. Taylor, N. R. et al. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. 41, 798-807 (1998).
40. Raag, R. & Poulos, T. L. Crystal structures of cytochrome P-450CAM complexed with camphane, thiocamphor, and adamantane: factors controlling P-450 substrate hydroxylation. Biochemistry 30, 2674-2684 (1991).
41. Watkins, R. E. et al. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science 292, 2329-2333 (2001).
42. Schumacher, M. A. et al. Structural mechanisms of QacR induction and multidrug recognition. Science 294, 2158-2163 (2001).
43. Sinha, N., Tsai, C.-J. & Nussinov, R. Building blocks, hinge bending motions and protein topology. J. Biomol. Struct. Dyn. 19, 369-380 (2001).
44. Teague, S. J., Davis, A. M., Leeson, R. D. & Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. Engl. 38, 3743 3748 (1999).
45. Arkin, M. R. et al. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl Acad. Sci. USA 100, 1603-1608 (2003).
46. Podust, L. M., Poulos, T. L. & Waterman, M. R. Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl Acad. Sci. USA 98, 3068-3073 (2001).
47. Ren, J. et al. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem. 275, 14316-14320 (2000).
48. Rose, R. B., Craik, C. S. & Stroud, R. M. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 37, 2607-2621 (1998).
49. Muzammil, S., Ross, P & Freire, E. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42, 631-638 (2003).
50. Vogeley, L., Palm, G. J., Mesters, J R. & Hilgenfeld, R. Conformational change of elongation factor TO (EF-Tu) induced by antibiotic binding. Crystal structure of the complex between EF-Tu, GDP and aurodox. J. Biol. Chem. 276, 17149-17155 (2001).
51. Luque, I. & Freire, E. Structural stability of binding sites: consequences for binding affinity and allosteric effects. Proteins 4, S63-S71 (2000).
52. Verkhivker, G. M. et al. Deciphering common failures in molecular docking of ligand-protein complexes. J. Comput. Aided Mol. Des. 14, 731-751 (2000).
53. Morton, A. & Matthews, B. W. Specificity of ligand binding in a buried nonpolar cavity of T4 lysozyme: linkage of dynamics and structural plasticity. Biochemistry 34, 8576-8588 (1995).
54. Murray, C. W., Baxter, C. A. & Frenkel, A. D. The sensitivity of the results of molecular docking to induced fit effects: application to thrombin, thermolysin and neuraminidase. J. Comput. Aided Mol. Des. 13, 547-562 (1999).
55. Carlson, H. A. Protein flexibility and drug design. How to hit a moving target. Curr. Opin. Chem. Biol. 6, 447-452 (2002).
56. Verkhivker, G. M. et al. Complexity and simplicity of ligand-macromolecule interactions: the energy landscape perspective. Curr. Opin. Struct. Biol. 12, 197-203 (2002).
57. Raves, M. L. et al. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nature Struct. Biol. 4, 57-63 (1997).
58. Wilson, D. K., Tarle, I., Petrash, J. M. & Quiocho, F. A. Refined 1.8 Å structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc. Natl Acad. Sci. USA 90, 9847-9851 (1993).
59. Urzhumtsev, A. et al. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 5, 601-612 (1997).
60. Todone, F. et al. Active site plasticity in D-amino acid oxidase: a crystallographic analysis. Biochemistry 36, 5853-5860 (1997).
61. 2+-CAM) by trifluoperazine (TFP). Protein Eng. 10, S47 (1997).
62. Pouplana, R., Perez, C., Sanchez, J., Lozano, J. J. & Puig-Parellada, P. The structural and electronic factors that contribute affinity for the time-dependent inhibition of PGHS-1 by indomethacin, diclofenac and fenamates. J. Comput. Aided Mol. Des. 13, 297-313 (1999).
63. Kurumbail, R. G. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644-648 (1996).
64. Steegborn, C., Laber, B., Messerschmidt, A., Huber, R. & Clausen, T. Crystal structures of cystathionine γ-synthase inhibitor complexes rationalize the increased affinity of a novel inhibitor J. Mol. Biol. 311, 789-801 (2001).
65. Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998).
66. Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the estrogen receptor. Nature 389, 753-758 (1997).
67. Suresh, S. et al. Conformational changes in Leishmania mexicana glyceraldehyde-3-phosphate dehydrogenase induced by designed inhibitors. J. Mol. Biol. 309, 423-435 (2001).
68. Rath, V. L. et al. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. 7, 677-682 (2000).
69. Hopkins, A. L. et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39, 1589-1600 (1996).
70. Ala, P. J. et al. Molecular recognition of cyclic urea HIV-1 protease inhibitors. J. Biol. Chem. 273, 12325-12331 (1998).
71. Tong, L. et al. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure 3, 33-40 (1995).
72. Melnick, M. et al. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design. J. Med. Chem. 39, 2795-2811 (1996).
73. Istvan, E. S. & Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 (2001).
74. Scrofani, S. D. B. et al. NMR characterization of the metallo-β-lactamase from Bacteroides fragilis and its interaction with a tight-binding inhibitor: role of an active-site loop. Biochemistry 38, 14507-14514 (1999).
75. Lovejoy, B. et al. Crystal structures of MMP-1 and - 13 reveal the structural basis for selectivity of collagenase inhibitors. Nature Struct. Biol. 6, 217-221 (1999).
76. Feng, Y et al. Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. Biochim. Biophys. Acta 1598, 10-23 (2002).
77. Brandstetter, H. et al. The 1.8-Å. crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J. Biol. Chem. 276, 17405-17412 (2001).
78. Raman, C. S. et al. Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry 40, 13448-13455 (2001).
79. Faig, M. et al. Structure-based development of anticancer drugs. Complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. Structure 9, 659-667 (2001)
80. Wang. Z. et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128 (1998).
81. Modi, S., Sutcliffe, M. J., Primrose, W. U., Lian, L.-Y. & Roberts, G. C. K. The catalytic mechanism of cytochrome P450 BM3 involves a 6 Å movement of the bound substrate on reduction. Nature Struct. Biol. 3, 414-417 (1996).
82. Raag, R., Li, H., Jones, B. C. & Poulos, T. L. Inhibitor-induced conformational change in cyctochrome P-450cam. Biochemistry 32, 4571-4578 (1993).
83. Poulos, T. L. & Howard, A. J. Crystal structures of metyrapone and phenylimidazole inhibited complexes of cytochrome P-450cam. Biochemistry 26, 8165-8174 (1987).
84. Schevitz, R. W. et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A. Nature Struct. Biol. 2, 458-465 (1995).
85. Chirgadze, N. Y. et al. The crystal structure of human α-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor Protein Sci. 6, 1412-1417 (1997).
86. Chirgadze, N. Y. et al. The crystal structures of human α-thrombin complexed with active site-directed diamino benzo-[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors. Protein Sci. 9, 29-36 (2000).
87. Tucker, T J. et al. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J. Med. Chem. 40, 830-832 (1997).
88. Stout, T. J. et al. Structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry 38, 1607-1617 (1999).
89. Sawaya, M. R. & Kraut, J. Loop and sub-domain movements in the mechanism of Escherichia coli dihydrofolate reductase: crystallographic evidence. Biochemistry 36, 586-603 (1997).
90. Krebs, W. G. & Gerstein, M. The morph server: a standardized system for analyzing and visualizing macromolecular motions in a database framework. Nucleic Acids Res. 28, 1665-1675 (2000).
91. Echols, N. D., Milburn, D. & Gerstein, M. MolMovDB: analysis and visualization of conformational change and structural flexibility. Nucleic Acids Res. 31, 478-482 (2003).